BOSTON — April 1, 2026 — Alloy Therapeutics today announced that Alexander Titus, Ph.D., has joined the company to lead its newly formed Vigilance Division, a strategic initiative focused on supply chain resilience, advancing biosecurity preparedness, and accelerating the development of therapeutics for emerging biological threats.

The Vigilance Division will collaborate with Alloy’s internal teams as well as government, philanthropic, and industry partners committed to global health and biotechnology security. It will prioritize rapid response to new and unforeseen biological risks, support resilient domestic and allied supply chains, and bring best-in-class AI tools to the mission. By leveraging Alloy’s integrated ecosystem, Vigilance aims to shorten development timelines, reduce costs per therapeutic candidate, and expand global partnerships to tackle critical biosecurity needs.

“Alloy is uniquely positioned to contribute to this mission because of its integrated ecosystem of discovery technologies, scientific expertise, and collaborative model,” said Dr. Titus. “By combining advanced biotechnology capabilities with next-generation software and AI tools, Alloy’s Vigilance Division will help accelerate the development of critical countermeasures while strengthening the resilience of the biotech innovation ecosystem.”

Titus has shaped biotechnology and AI initiatives across government, industry and academia. He was the first biotechnology strategy lead at the U.S. Department of Defense and has held leadership roles at Avidity Biosciences, Colossal Biosciences, and Google Cloud. He currently serves as a Commissioner on the U.S. National Security Commission on Emerging Biotechnology, has held academic and research positions at the University of Southern California and Georgetown University, and writes extensively on the evolving relationship between technology and public policy.

“Dr. Titus brings a rare combination of expertise in biotechnology, AI, and national security that makes him well suited to lead our Vigilance Division,” said Errik Anderson, Chief Executive Officer and Founder of Alloy Therapeutics. “His leadership will be critical as we build this capability and further strengthen Alloy’s ability to respond quickly to urgent health challenges while driving innovation across our integrated ecosystem.”

About Alloy Therapeutics
Alloy Therapeutics is a biotechnology ecosystem company empowering the future of drug discovery and development with AI-powered platforms and scientific expertise. Through a collaborative partnership approach, Alloy provides access to technologies, services, and company-creation capabilities that are foundational to discovering and developing therapeutic biologics across multiple modalities: antibodies, bispecifics, TCRms, genetic medicines, cell therapies, and drug delivery.

Alloy integrates AI/ML into its discovery and development infrastructure, combining proprietary models, real-world data, and human expertise to help partners advance therapeutic programs. At Alloy, we are redefining biologics development by reducing the time and cost to advance programs from discovery to human data. Join the Alloy Therapeutics community by visiting www.alloytx.com and following Alloy on LinkedIn.


Alloy Therapeutics Media Contact:

Hal Mackins
hal@torchcomllc.com